Get Started in Minutes
How Mvasi Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Mvasi?
Mvasi is a prescription medication used to treat various kinds of cancer. It is a type of medication called monoclonal antibodies, similar to antibodies that our bodies make to protect us when an unwanted substance enters our bodies. In the case of Mvasi, the antibody is recombinant humanized, which means its protein sequences have been modified to increase its similarity to those produced naturally in our bodies, making it safe for human administration. Mvasi is a vascular endothelial growth factor (VEGF) inhibitor. It inhibits microvascular growth which retards the growth of all tissues (including metastatic cancer tissue). It was approved in 2017 as the first biosimilar to Avastin. A biosimilar is a medicine that is nearly identical to another drug in terms of structure and function. The generic name of Mvasi is bevacizumab-awwb.
Mvasi is available as 100 mg and 400 mg single-use vials. It is a slightly opalescent, colorless to pale yellow solution that contains 25 mg/ml of bevacizumab-awwb.
Mvasi is only administered as an intravenous (IV) infusion. This drug is manufactured by Amgen, Inc.
What Is Mvasi Used To Treat?
- Metastatic Colorectal Cancer: Mvasi is used in combination with intravenous 5-fluorouracil–based chemotherapy as the first- or second-line treatment for patients with metastatic colorectal cancer. Mvasi is also used in combination with fluoropyrimidine-irinotecan- or fluoropyrmidine-oxaliplatin-based chemotherapy as a second-line treatment if the cancer progresses after first-line treatment that includes bevacizumab.
- Non-Squamous Non–Small Cell Lung Cancer: Mvasi is used in combination with carboplatin and paclitaxel as the first-line treatment of unresectable, recurrent, locally advanced, or metastatic non–squamous non–small cell lung cancer.
- Recurrent Glioblastoma: Mvasi is used to treat adults who have recurrent glioblastoma.
- Metastatic Renal Cell Carcinoma: Mvasi is used in combination with interferon alfa to treat metastatic renal cell carcinoma.
- Cervical Cancer: For cervical cancer that is persistent, recurrent, or metastatic, Mvasi is used in combination with paclitaxel and topotecan or paclitaxel and cisplatin.
- Ovarian (epithelial), Fallopian Tube, or Primary Peritoneal Cancer:
- Mvasi is used in the treatment of Stage III or IV disease, following initial surgical resection. It is used in combination with carboplatin and paclitaxel. This is followed by single-agent treatment with bevacizumab.
- Mvasi is used in the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is used in combination with paclitaxel, doxorubicin (liposomal), or topotecan in patients who received no more than two prior chemotherapy regimens.
- Mvasi is used in the treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is used in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by single-agent bevacizumab.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Mvasi Side Effects
Common side effects include:
- High blood pressure
- Peripheral edema (swelling of the lower legs or hands)
- Blood clots
- Severe shedding of the top layers of the skin
- High blood glucose
- Increase in blood albumin
- Electrolyte imbalance (decrease in blood magnesium & sodium)
- Ovarian failure (a condition in which the ovaries stop working and menstrual periods can stop before age 40)
- Weight loss
- Abdominal pain
- Decreased appetite
- Mouth sores
- Pain in the lower abdominal region
- Urinary tract infection
- Skin bruising
- Low white blood cell count
- Bleeding into lower respiratory tract
- Very low platelet count
- Slurred speech
- Difficulty sleeping
- Muscle weakness
- Changes in the voice
- Joint pain
- Arm or leg pain
- Muscle pain
- Decrease in kidney function (increased serum creatinine)
- Pain in the mouth or throat
- Inflammation of the sinuses
- Runny nose
- Protein in the urine
- Changes in taste
- Dry skin
- Dry or watery eyes
- Skin redness and peeling
- Rectal bleeding
Serious side effects include:
- Swelling of the lips, face, tongue, or throat
- Difficulty breathing
- Shortness of breath
- Easy bruising
- Chest pain
- Unusual bleeding
- Severe stomach pain
- Bloody or tarry stools
- Any bleeding that will not stop
- Coughing up blood
- Sudden, severe headache
- Problems with vision or balance
- Vomit that resembles coffee grounds
- Sudden numbness or weakness
- Extreme weakness
- Extreme tiredness
- Vision problems
- Stomach pain or swelling
- Urine leakage
- Chest pain and trouble breathing
- Choking or gagging feeling when eating or drinking
- Redness, pain, swelling, or warmth in one or both legs
- Missed menstrual periods
- Puffy eyes
- Chest pain
- Pain spreading to the jaw or shoulder
- Rapid weight gain
- Swelling in the ankles or feet
- Urine that looks foamy
- Sore throat
- Mouth sores
- Skin sores
- Blurred vision
- Pounding in the neck or ears
- Sudden redness, warmth, oozing, or swelling
- Any skin wound or surgical incision that does not heal
Mvasi Dosing Information
Depending on the diagnosis, treatment could either be for a set number of cycles or might have to be continued until there is unacceptable toxicity or disease progression. Below are the recommended doses for each condition treated by Mvasi:
- Metastatic Colorectal Cancer: The recommended dosage is 5 mg/kg or 10 mg/kg every 2 weeks. The dosage will vary depending on what drug is used in combination.
- When combined with the bolus-IFL regimen, administer 5 mg/kg every 2 weeks.
- When combined with the FOLFOX4 regimen, administer 10 mg/kg every 2 weeks.
- When combined with a fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy drug, administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks.
- Non-Squamous Non-Small Cell Lung Cancer: In combination with carboplatin and paclitaxel, the dose recommendation is 15 mg/kg every 3 weeks for 6 cycles.
- Recurrent Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks as a single agent treatment.
- Metastatic Renal Cell Carcinoma (mRCC): In combination with interferon alfa, the recommended dose is 10 mg/kg every 2 weeks.
- Cervical Cancer: Mvasi should be used in combination with paclitaxel and topotecan, or paclitaxel and cisplatin. The recommended dose of Mvasi is 15 mg/kg every 3 weeks as an intravenous infusion.
- Ovarian, Fallopian Tube, or Primary Peritoneal Cancer:
- Stage III or IV disease following initial surgical resection: The dose recommendation is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by Mvasi (monotherapy) dosed at 15 mg/kg every 3 weeks for a total of up to 22 cycles or until disease progression.
- Recurrent, platinum-resistant: The recommended dose is 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks in combination with paclitaxel, doxorubicin (liposomal), or topotecan.
- Recurrent, platinum-sensitive: The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and gemcitabine for 6 to 10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles, followed by Mvasi (monotherapy) until disease progression or unacceptable toxicity.